Hein P. J. Visser

The Polycomb group protein EZH2 is upregulated in proliferating, cultured human mantle cell lymphoma

Hein P. J. Visser, Marco J. Gunster, Hanneke C. Kluin‐Nelemans et al. · British Journal of Haematology · 2001 · 229 citations

Life Sciences, Genetics, Oncology +16

First-line venetoclax combinations versus chemoimmunotherapy in fit patients with chronic lymphocytic leukaemia (GAIA/CLL13): 4-year follow-up from a multicentre, open-label, randomised, phase 3 trial

Moritz Fürstenau, Arnon P. Kater, Sandra Robrecht et al. · The Lancet Oncology · 2024 · 77 citations · Full text

Medicine, Oncology, Pharmacotherapy +12

Quality of life of patients with chronic lymphocytic leukaemia in the Netherlands: results of a longitudinal multicentre study

Kim Holtzer-Goor, Martyn Ronald Schaafsma, Peter Joosten et al. · Quality of Life Research · 2015 · 54 citations · Full text

Medicine, Hematology, Oncology +16

Venetoclax consolidation after fixed-duration venetoclax plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (HOVON 139/GiVe): primary endpoint analysis of a multicentre, open-label, randomised, parallel-group, phase 2 trial

Sabina Kersting, Julie Dubois, Kazem Nasserinejad et al. · The Lancet Haematology · 2022 · 31 citations · Full text

Medicine, Hematology, Pharmacology +3

Fixed-duration venetoclax plus obinutuzumab improves quality of life and geriatric impairments in FCR-unfit patients with CLL

Lina van der Straten, Claudia A.M. Stege, Sabina Kersting et al. · Blood · 2023 · 28 citations · Full text

Medicine, Geriatric Medicine, Pharmacotherapy +6